4.5 Review

Materials based tumor immunotherapy vaccines

Journal

CURRENT OPINION IN IMMUNOLOGY
Volume 25, Issue 2, Pages 238-245

Publisher

CURRENT BIOLOGY LTD
DOI: 10.1016/j.coi.2012.12.008

Keywords

-

Categories

Funding

  1. NIH [R01 DE019917]
  2. NSF GRFP
  3. Wyss Institute

Ask authors/readers for more resources

Immunotherapy is a promising approach for treating cancer. However, there are limitations inherent to current approaches which may be addressed by integrating them with biomaterial-based strategies. Material platforms have been fabricated to interact with immune cells through spatially controlled and temporally controlled delivery of immune modulators and to promote immune cell crosstalk. Particle vaccines have been developed to specifically target and deliver agents to organs, cells and subcellular compartments. These strategies have been shown to generate antigen-specific CTL responses and, in some cases, tumor regression. Therefore, collaboration between immunology and materials engineering is likely to result in the creation of strong vaccines to combat cancer in the future.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available